That is what I’m suggesting too. In the announcement, the operative word from Mo is that it will ’truly’ make it a ‘Lab-on-a-Chip’. Rather than it being a chip-in-a-lab which the industry would have their investors believe.
The global clinical laboratory services industry was valued at US$ 313.3 Billion in 2021. The Market size is expected to be worth around USD 886.5 Billion by 2032 from USD 450.1 Billion in 2022, growing at a CAGR of 7.2%. (see article)
If AXE’s Lab-on-a-Chip technology can integrate one or more laboratory processes or techniques onto a single miniaturised chip that will take away the role (in part or whole) for the need for elaborate and costly laboratories. This is clearly a threat to those who have invested in this industry thinking that the cash-cow, that it is, will continue for some time yet.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)